About this trial
The planned randomized, sham-controlled, double-blind, monocentric study aims to evaluate the effectiveness of intermittent Theta-Burst Stimulation (iTBS) on negative symptoms and cognitive deficits in schizophrenia. Both the cerebellar vermis and the left dorsolateral prefrontal cortex will be stimulated successively within the same session.
The goal of this trial is to learn if intermittent theta-burst stimulation (iTBS) of the cerebellum and the left dorsolateral prefrontal cortext (DLPFC) can treat negative symptoms and improve cognition in patients with schizophrenia. The main question it aims to answer is:
Does iTBS of the cerebellum and the left DLPFC improve negative symptoms in patients with schizophrenia? Researchers will compare iTBS to sham stimulation to see if iTBS improves negative symptoms.
Participants will:
* Receive 10 sessions of iTBS over the course of 2 weeks * Undergo extensive examination before iTBS treatment, immediately after iTBS treatment and 4 weeks after iTBS treatment. The examination includes assessment of negative symptoms; psychometric assessment of cognition, social cognition, depressive symptoms; functional magnetic resonance imaging; assessment of eye movements; blood and saliva sampling; assessment of adverse events and stimulation associated sensations.
The study thus seeks to determine whether iTBS of the fronto-cerebellar network might improve negative symptoms and cognition by altering the network's functional activity. Additionally, it will investigate whether a pro-inflammatory cytokine profile could affect iTBS outcomes and whether inflammatory markers could be affected by iTBS.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of schizophrenia (ICD-10: F20.-)
Age: 18-65 years
Ability to give informed consent
Signed informed consent form
Disqualifiers
Any electronic implants
Non-MRI-compatible metal implants (e.g., pacemaker, cochlear implant, insulin pump, metal fragment injuries, work in the metal-processing industry)
Non-TMS-compatible metal implants (compatible items include: earrings, piercings, dental fillings, crowns, implants)
Claustrophobia
Trial design
Parallel
Treatments tested in this trial
Intermittent theta-burst stimulation
DeviceIntermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
Sham intermittent theta-burst stimulation
DeviceSham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
Treatment groups
Trial outcomes
Primary outcomes
Change in negative symptoms
Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.
Secondary outcomes
Change in negative symptoms at 4-week follow-up
Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.
Speech-gesture rating task
Accuracy and speed of evaluations in the Speech-Gesture Rating Task.
Speech-gesture rating task at 4-week follow-up
Accuracy and speed of evaluations in the Speech-Gesture Rating Task at 4-week follow-up.
Eye-Tracking Task
Changes in eye movements in the Eye-Tracking Task.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.